XML 9 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
The following table discloses additional compensation information of (i) our Chief Executive Officer and (ii) all other named executive officers (the "Other NEOs"), including "compensation actually paid" during the specified years alongside total shareholder return ("TSR") and net income metrics:
Value of initial fixed $100 investment based on:
Year(1)
Summary compensation table total for CEO
($)
Compensation actually paid to CEO(2)(3)
($)
Average summary compensation table
total for Other NEOs
($)
Average Compensation actually paid to Other
NEOs(2)(4)
($)
Total shareholder return(5)
($)
Peer group total shareholder return(5)
($)
Net income(6)
($ millions)
20259,656,813 17,732,855 3,553,996 6,043,950 89.87 87.60 (353)
20247,279,504 4,803,366 2,793,357 1,696,346 147.43 95.43 (283)
202310,120,945 7,480,720 4,193,925 2,953,574 194.36 94.37 (307)
20229,048,432 (2,065,105)4,191,618 (2,394,074)204.75 87.61 (267)
20219,483,339 14,577,932 5,939,512 7,091,681 400.69 117.83 53 
        
Named Executive Officers, Footnote Our Chief Executive Officer for each of the years presented was Dr. Rosen. Our Other NEOs for 2025 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett, and Richard Markus. Our other NEOs for 2024, 2023 and 2022 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett and Dimitry Nuyten. Our Other NEOs for 2021 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett, Carolyn Tang and William Grossman.        
Peer Group Issuers, Footnote TSR figures assume an initial investment in our common stock of $100 on December 31, 2020. The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 25.        
PEO Total Compensation Amount $ 9,656,813 $ 7,279,504 $ 10,120,945 $ 9,048,432 $ 9,483,339
PEO Actually Paid Compensation Amount $ 17,732,855 4,803,366 7,480,720 (2,065,105) 14,577,932
Adjustment To PEO Compensation, Footnote The adjustments made to the summary compensation table total for Dr. Rosen for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below:
2025
Summary compensation table total9,656,813 
Less, value of stock & option awards(8,208,310)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding11,505,469 
Plus change in fair value of prior year awards that are outstanding and unvested2,682,647 
Plus FMV as of the vesting date of awards granted this year and that vested this year2,069,034 
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year27,202 
Total adjustments8,076,042 
Compensation actually paid to CEO17,732,855 
        
Non-PEO NEO Average Total Compensation Amount $ 3,553,996 2,793,357 4,193,925 4,191,618 5,939,512
Non-PEO NEO Average Compensation Actually Paid Amount $ 6,043,950 1,696,346 2,953,574 (2,394,074) 7,091,681
Adjustment to Non-PEO NEO Compensation Footnote The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other NEOs in such year are shown in the tables below:
2025
Summary compensation table total3,553,996 
Less, value of stock & option awards(2,620,761)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding3,770,503 
Plus change in fair value of prior year awards that are outstanding and unvested714,294 
Plus FMV as of the vesting date of awards granted this year and that vested this year619,113 
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year6,805 
Total adjustments2,489,954 
Compensation actually paid to Other NEOs6,043,950 
        
Compensation Actually Paid vs. Total Shareholder Return
The graphs below show the relationship between (i) the compensation actually paid to both our Chief Executive Officer and the Other NEOs for the years set forth in the Pay versus Performance Table, (ii) our net income/loss and (iii) total shareholder return for us and our peer group for the corresponding years:
3984
        
Compensation Actually Paid vs. Net Income
The graphs below show the relationship between (i) the compensation actually paid to both our Chief Executive Officer and the Other NEOs for the years set forth in the Pay versus Performance Table, (ii) our net income/loss and (iii) total shareholder return for us and our peer group for the corresponding years:
3982
        
Total Shareholder Return Vs Peer Group
The graphs below show the relationship between (i) the compensation actually paid to both our Chief Executive Officer and the Other NEOs for the years set forth in the Pay versus Performance Table, (ii) our net income/loss and (iii) total shareholder return for us and our peer group for the corresponding years:
3984
        
Total Shareholder Return Amount $ 89.87 147.43 194.36 204.75 400.69
Peer Group Total Shareholder Return Amount 87.60 95.43 94.37 87.61 117.83
Net Income (Loss) $ (353,000,000) $ (283,000,000) $ (307,000,000) $ (267,000,000) $ 53,000,000
PEO Name Dr. Rosen Dr. Rosen Dr. Rosen Dr. Rosen Dr. Rosen
Additional 402(v) Disclosure Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date.TSR figures assume an initial investment in our common stock of $100 on December 31, 2020.Reflects after-tax net income attributable to stockholders prepared in accordance with GAAP for each of the years shown. The Company does not use any financial performance measure to link compensation actually paid to company performance.        
PEO          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 8,076,042        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (8,208,310)        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 11,505,469        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,682,647        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,069,034        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 27,202        
Non-PEO NEO          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,489,954        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,620,761)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,770,503        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 714,294        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 619,113        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 6,805